Amyn eligibility engine Amyneion demo build 0.1100% synthetic data, no PHI
9 trial protocols across 7 conditions, against synthetic community panels of 2,000 and 1,200 patients, screened by the deterministic Amyn matching engine. Every verdict is criterion-level and cites its evidence. Time-to-eligibility is arithmetic on documented medication dates, not a predictive model.
Protocol design is an inclusion lever
Eligible patients by protocol design, each scored against its own synthetic panel. The broad pragmatic lupus design finds more than twice the patients of the narrow one.
Which criterion costs the most patients
Patients excluded by exactly one criterion (everything else passing), for the selected protocol. The underrepresented share of each bar shows where a criterion relaxation buys inclusion.
Eligible population vs disease burden
Share of the eligible pool by group. Where a published, citable share of prevalent US SLE cases exists, it is shown alongside and the gap is the integrity metric Amyneion reports. Groups without a sourced share are reported without a comparison rather than against an unverified figure.
The pipeline nobody else sees
Patients not eligible today whose blocking criterion resolves by a known date: biologic washouts ending, steroid tapers completing. This is recruitment as a forecast, not a search.
Navigator queue, selected protocol
Top matches ranked by disease activity, with the evidence a navigator sees before the first call. Barrier flags route each patient to the right CARRY package: rides, home draws, Spanish-language outreach.
What-if: relax the costliest criterion
The COMPILE simulator re-runs matching with one criterion removed. This is the protocol design feedback sponsors get before site selection.